FDA approves Opdivo for bladder cancer

FDA granted accelerated approval to Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) to treat locally advanced or metastatic urothelial carcinoma that has progressed on or after platinum-containing chemotherapy.

Opdivo is the second checkpoint inhibitor to receive FDA approval for the indication. In May, FDA granted accelerated approval to rival PD-L1 inhibitor Tecentriq atezolizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) (see BioCentury Extra, May 18, 2016)...